PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Additional Paid-In Capital

Last Annual Value

508.54M

3-Year CAGR

22%

5-Year CAGR

432%

10-Year CAGR

55%

PepGen Inc.

PepGen Inc. Competitors Analysis of Additional Paid-In Capital

PEPG · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
508.54M
20.6%214.5%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
0.00
N/AN/AN/A
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
960.22M
10.7%16.1%N/A
631.18M
11.8%13.9%N/A
162.53M
209.8%N/AN/A
352.75M
303.4%272.3%N/A
995.22M
8.7%8.6%N/A
0.00
N/AN/AN/A
840.94M
1.4%2.1%N/A
0.00
N/AN/AN/A
702.98M
17.8%10.9%32.5%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642